Oklahoma City, OK – (August 9, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of a Dr. Jesse McCool to its Board of Directors
Dr. McCool, Ph.D., currently serves as Cytovance’s Sr. Vice President of Research & Development. “Dr. McCool embodies the spirit of community and brings talent, expertise and energy to the table. We are very fortunate to have Dr. McCool by our side as we continue to grow and strengthen Cytovance Biologics”, said Darren Head, President and Chief Executive Officer of Cytovance Biologics. “I’m confident Dr. McCool will make enormous contributions and bring tremendous technical, operational and leadership expertise to the table.”
Dr. McCool, Ph.D., has over 20 years of experience in microbial process development, process characterization and technology transfer. Prior to Cytovance, Dr. McCool was the Director of Process Development at Lonza. In this role he expanded offerings in Microbial R&D Services and improved market presence through driving new technologies development, particularly in the areas of strain development, design-of-experiments (DoE), and late-stage program support. He helped to adopt a QbD framework for supporting pre-validation activities and supported numerous cGMP campaigns as a subject matter expert.
As an established speaker, he has chaired and presented at various industry conferences including Recent Advances in Fermentation Technology, Society for Industrial Microbiology and Biotechnology, Biotechnology Industry Organization, and International Society for Pharmaceutical Engineering. He has written and contributed to numerous published papers on topics including fermentation process design and microbial expression technologies. Previous to Lonza, Dr. McCool served as Scientist at Mascoma Corporation in Lebanon, NH and Postdoctoral Research Associate at the Thayer School of Engineering at Dartmouth College, in Hanover, NH.
“I am honored to join the Board of Directors of Cytovance and Hepalink”, said Dr. McCool. “I look forward to supporting the management team and board in translating their efforts into Cytovance’s continued success.”
About Cytovance® Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.